CX Institutional’s Harmony Biosciences HRMY Stock Holding History

CX Institutional’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.55M	Sell	217,882 -41,614	-16%	-$1.61M	0.23%	105
2026 Q2	$9.45M	Buy	259,496 +14,809	+6%	+$467K	0.27%	82
2026 Q1	$6.85M	Sell	244,687 -31,122	-11%	-$1.02M	0.21%	114
2025 Q4	$10.3M	Buy	275,809 +45,376	+20%	+$1.49M	0.31%	75
2025 Q3	$6.35M	Buy	230,433 +22,650	+11%	+$780K	0.19%	126
2025 Q2	$6.57M	Buy	207,783 +129,916	+167%	+$4.18M	0.23%	100
2025 Q1	$2.58M	Buy	+77,867	New	+$2.79M	0.1%	167

Other funds holding HRMY

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $4.07B AUM 38.25% 1-Year Est. Return

BNA

BankChampaign National Association Champaign, Illinois $120M AUM 54.13% 1-Year Est. Return

CX Institutional's HRMY Position: Q3 2026 in Review

CX Institutional reduced its Harmony Biosciences (HRMY) stake by 16% in Q3 2026, selling an estimated $1.61M and leaving 217,882 shares worth $8.55M. The position accounts for 0.23% of the portfolio, ranked #105.

CX Institutional first reported a position in HRMY in Q1 2025 and has held it in 7 quarters since. The position peaked at $10.3M in Q4 2025. 27 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

CX Institutional held 217,882 shares of Harmony Biosciences worth $8.55M as of Q3 2026.
CX Institutional sold 41,614 Harmony Biosciences shares in Q3 2026, an estimated $1.61M.
Harmony Biosciences made up 0.23% of CX Institutional's portfolio in Q3 2026, its #105 holding.
CX Institutional first reported a position in Harmony Biosciences in Q1 2025 and has held it in 7 quarters since.
CX Institutional's Harmony Biosciences position peaked at $10.3M in Q4 2025.
27 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.